Current Edition

diabetes

FDA chides Eli Lilly for second misleading ad in 2 months, this time for diabetes blockbuster Trulicity

After neatly wrapping up concerns over a series of Emgality ads last month, Eli Lilly is back in hot water with the FDA’s Office of …

Continue Reading →
AbbVie

Eyeing its post-Humira future, AbbVie angles for broader Rinvoq use in U.S., Europe

Despite classwide safety worries in the U.S., AbbVie is making strides in its quest to build immunology up-and-comer Rinvoq. AbbVie sent off applications to U.S. and …

Continue Reading →
criminal case

Former pharma CEO plundered millions from his own company, DOJ says

What not to do with millions of dollars of a pharma company’s cash? Don’t allegedly cover personal credit card bills and pay for tuition for …

Continue Reading →
COVID-19 pill

Buffett’s Berkshire exited Merck investment just before COVID pill boost, further trimmed AbbVie and BMS holdings

Warren Buffett’s Berkshire Hathaway doesn’t appear to be the oracle of every market movement, at least not in the case of an investment in Merck …

Continue Reading →
drugmaker

Ipsen poaches Novartis vet Scheiffele to serve as president of its international specialty care team

Amid its push to grow around the globe in oncology, rare diseases and neuroscience, Ipsen has poached a Novartis veteran to head up its international …

Continue Reading →
anti-CGRP

Biohaven’s Nurtec, with dual migraine approvals, hits $136M in quarterly sales and leads the pack in market share

Biohaven’s migraine drug Nurtec ODT has been on a roll since becoming the first medicine to win a dual FDA approval to both treat and …

Continue Reading →